|
|||||
|
|
An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus |
|
| Authors: | Hatta Yasuko Hatta Masato Bilsel Pamuk Neumann Gabriele Kawaoka Yoshihiro |
| Affiliation: | a Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA b FluGen, Inc., Madison, WI 53711, USA c Division of Virology, Department of Microbiology and Immunology; Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan d ERATO Infection-Induced Host Responses Project, Japan Science and Technology Agency, Saitama 332-0012, Japan |
| Abstract: | The 2009 influenza pandemic brought home the importance of vaccines in infection control. Previously, we demonstrated an M2 cytoplasmic tail mutant H5N1 influenza virus could serve as a live-attenuated vaccine. Here, we adapted that strategy, generating a mutant pandemic (H1N1) 2009 virus that grew well in cell culture, but replicated less well in mice than did wild-type virus. The mutant virus elicited sterile immunity in mice, completely protecting them from challenge with a pandemic (H1N1) 2009 virus. Our results indicate that M2 cytoplasmic tail mutants are suitable for live-attenuated vaccines against pandemic viruses. |
| Keywords: | Influenza vaccine Pandemic (H1N1) 2009 Live attenuated vaccine M2 deletion |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |